An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions
about
Evolving Paradigm of Radiotherapy for High-Risk Prostate Cancer: Current Consensus and Continuing ControversiesCombination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I studyFailure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapyRadiotherapy in prostate cancer treatment: results of the patterns of care study in KoreaDifferent rectal toxicity tolerance with and without simultaneous conventionally-fractionated pelvic lymph node treatment in patients receiving hypofractionated prostate radiotherapy.Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancerAndrogen deprivation therapy for prostate cancer-review of indications in 2010Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.Contemporary role of androgen deprivation therapy for prostate cancerThe early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancerToxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer.Is neoadjuvant androgen deprivation therapy beneficial in prostate cancer treated with definitive radiotherapy?Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910.Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease control.Hormone therapy in the management of prostate cancer: evidence-based approachesFinal Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate CancerImpact of the duration of hormonal therapy following radiotherapy for localized prostate cancer.HDR Brachytherapy in the Management of High-Risk Prostate Cancer.Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.The current role of androgen deprivation in patients undergoing dose-escalated external beam radiation therapy for clinically localized prostate cancer.Tissue biomarkers for prostate cancer radiation therapy.Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapySelect men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy.Improved survival with the addition of radiotherapy to androgen deprivation: questions answered and a review of current controversies in radiotherapy for non-metastatic prostate cancer.Analysis of Geometric Shifts and Proper Setup-Margin in Prostate Cancer Patients Treated With Pelvic Intensity-Modulated Radiotherapy Using Endorectal Ballooning and Daily Enema for Prostate ImmobilizationA prospective comparison of acute intestinal toxicity following whole pelvic versus small field intensity-modulated radiotherapy for prostate cancer.Comparison study of intensity modulated arc therapy using single or multiple arcs to intensity modulated radiation therapy for high-risk prostate cancer.Use of androgen deprivation therapy in prostate cancer: indications and prevalence.The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer.Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005.Radiotherapy and Hormone Treatment in Prostate CancerThe Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups.Anatomical Patterns of Recurrence Following Biochemical Relapse in the Dose Escalation Era of External Beam Radiotherapy for Prostate Cancer.Benefit of whole pelvic radiotherapy combined with neoadjuvant androgen deprivation for the high-risk prostate cancer.Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT).Radiation therapy approaches to the treatment of high-risk prostate cancer.Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer.Whole pelvic intensity-modulated radiotherapy for high-risk prostate cancer: a preliminary report.Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?
P2860
Q26744606-5412DBF9-3D72-4FBB-8CEF-176F8229E0C4Q28218423-34DFE10A-01DD-47EC-BC37-E7BAA890E299Q31028126-C311D646-12FF-43C5-9B03-5316146E599BQ31083823-04ADAE7B-4CC2-4D2D-B571-6FBAD63C9536Q33583944-F2F7CC85-E3C1-449E-BA6C-640244B3294DQ33765122-050DCE9B-9E28-4905-8DAE-B1319E151533Q34104391-3848AE2E-59A2-4D4C-A40F-B77F0486EC62Q34111603-9349F3F2-7236-4922-AB19-FA428474E0B6Q34187079-9E4B2E27-7042-425B-A13E-DA61789012E9Q34211155-901F5D6A-30B9-4E57-B2E3-85F1668BC28DQ34433023-3E2AB774-49C6-46B7-BB5D-D361CCD15929Q34611812-042BFD6B-BFA5-4572-B6C1-293FE607CA85Q34810730-DAC62E93-2F2B-4A25-98D9-0D04205BA6ECQ34996654-2DC39CAE-7FDC-42BE-A12A-300F96F6C040Q34998545-538FC9F0-1949-4978-8780-A1E4C4AE39E0Q35076432-35B8D5DE-5311-4A22-B70E-452C8DFAB0F6Q35771166-5DE6EDFD-E10A-4BC0-B8F9-CE0F21EE1D56Q35803832-BADC4288-8C7B-49F3-945F-ACB4A605D359Q35810413-295ED245-C1F1-4AAA-A5DF-BD20A8760250Q35835108-366F07CE-A874-40AB-B4BC-31B52D38B051Q35947920-395BA4F5-951B-480E-B391-0BA6B7690A30Q36141341-7F8E2567-3CD6-4766-A14B-4FAAE6A45B6CQ36293177-F172A6E7-EFFF-473A-9AD1-8386D96F7C9EQ36360358-0B8FCF3D-78F6-43C6-B4EB-3A6B294A81FBQ36474222-F75FA6ED-12A7-4881-98AB-55BFC683236DQ36478072-E4163DEF-8F02-48C4-BEF2-E266DD6B9534Q36684017-2680DB00-8694-4474-837C-D8395F6E0FFEQ37015346-6436ED2D-CE2A-4BCE-A8A0-35B5B588D901Q37074379-83711592-90F6-47DC-AE2B-FB30FC172411Q37154093-B58AC224-0144-4D34-8DEB-4EF4DFFAE44DQ37158281-B22518E4-0591-469F-97BF-04FCB0DF6344Q37176612-498D9B7A-333F-45D4-A1F5-C4EDC59327DFQ37195789-7214C0E6-27AD-48B8-A14B-19338D58945DQ37214143-C5EEC027-6A89-4468-8527-AA60743325AFQ37396108-4AD414DA-F85A-49C7-95E9-B2815EC779AFQ37401422-FBDD08E6-544B-45C1-90ED-A2F3F90A3E52Q37446029-535D8671-9D4D-4BBA-B529-5CB7ACC0B83BQ37460247-ED5454DF-F387-4B4A-8D07-BB3ED01A65FAQ37549491-49EEAEC3-233F-4192-89FF-B6A74FDAB3AEQ37563875-B9B60410-B28C-45BA-A194-8E2B80A204BC
P2860
An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
An update of the phase III tri ...... hormone/radiation interactions
@ast
An update of the phase III tri ...... hormone/radiation interactions
@en
An update of the phase III tri ...... hormone/radiation interactions
@nl
type
label
An update of the phase III tri ...... hormone/radiation interactions
@ast
An update of the phase III tri ...... hormone/radiation interactions
@en
An update of the phase III tri ...... hormone/radiation interactions
@nl
prefLabel
An update of the phase III tri ...... hormone/radiation interactions
@ast
An update of the phase III tri ...... hormone/radiation interactions
@en
An update of the phase III tri ...... hormone/radiation interactions
@nl
P2093
P2860
P1476
An update of the phase III tri ...... hormone/radiation interactions
@en
P2093
Charles R Thomas
Christopher Jones
Colleen A Lawton
Marvin Rotman
Michael Seider
Michelle DeSilvio
Richard Valicenti
Robert Kirsch
Stephen Hahn
Sucha Asbell
P2860
P304
P356
10.1016/J.IJROBP.2007.04.003
P407
P50
P577
2007-05-24T00:00:00Z